EDITAS MEDICINE, INC. Total Liabilities and Equity
EDITAS MEDICINE, INC. (EDIT) had Total Liabilities and Equity of $237.36 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-05
- 2026-06-30: Liabilities and Equity $237.36M.
- 2026-03-31: Liabilities and Equity $149.34M.
- 2025-12-31: Liabilities and Equity $186.53M.
- 2025-09-30: Liabilities and Equity $201.75M.
| Period end | Liabilities and Equity |
|---|---|
| 2026-06-30 | $237.36M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $149.34M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $186.53M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $201.75M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $210.58M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $263.65M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $341.59M 10-K · filed 2026-03-09 |
| 2024-09-30 | $327.57M 10-Q · filed 2024-11-04 |
| 2024-06-30 | $384.80M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $440.35M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $499.15M 10-K · filed 2025-03-05 |
| 2023-09-30 | $504.65M 10-Q · filed 2023-11-03 |
| 2023-06-30 | $541.95M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $464.11M 10-Q · filed 2023-05-05 |
| 2022-12-31 | $514.32M 10-K · filed 2024-02-28 |
| 2022-09-30 | $531.03M 10-Q · filed 2022-11-02 |
| 2022-06-30 | $580.83M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $623.11M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $677.48M 10-K · filed 2023-02-22 |
| 2021-09-30 | $717.02M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $755.88M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $780.29M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $572.60M 10-K · filed 2022-02-24 |
| 2020-09-30 | $597.16M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $655.48M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $466.74M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $508.88M 10-K · filed 2021-02-26 |
| 2019-09-30 | $372.36M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $355.63M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $378.92M 10-Q · filed 2019-05-08 |
| 2018-12-31 | $420.39M 10-K · filed 2020-02-26 |
| 2018-09-30 | $387.63M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $393.53M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $403.98M 10-Q · filed 2018-05-04 |
| 2017-12-31 | $373.26M 10-K · filed 2019-03-01 |
| 2017-09-30 | $339.13M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $368.85M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $395.04M 10-Q · filed 2017-05-15 |
| 2016-12-31 | $229.18M 10-K · filed 2018-03-08 |
| 2016-09-30 | $242.15M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $249.60M 10-Q · filed 2016-08-10 |
| 2016-03-31 | $248.81M 10-Q · filed 2016-05-13 |
| 2015-12-31 | $149.36M 10-K · filed 2017-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |